Demon Lord Arlatoskr, the Hound of Hell
LightNews LightNews
arlatoskr.bsky.social
Demon Lord Arlatoskr, the Hound of Hell
@arlatoskr.bsky.social
230 followers 430 following 1 posts
26 y/o | He/Him | 18+ Account that's just here to appreciate Art and spread the word about things that matter to me. | BLM | Trans Rights are Human Rights
Posts Replies Media Videos
Reposted by Demon Lord Arlatoskr, the Hound of Hell
sailorrooscout.bsky.social
Researchers envision their vaccine being used as both a treatment and a preventive, and as an approach to treating multiple cancer types. NOTE: This is PRECLINICAL.
• www.umass.edu/news/article...

The study has been published in Cell. YES, it is PEER-REVIEWED.
• www.cell.com/cell-reports...

🧪🧵⬇️
HIGHLIGHTS • Lipid NPs carrying STING and TLR4 agonists promote synergistic type I interferons • NPs drain efficiently to lymph nodes and increase polyfunctional T and B cells • NPs improve tumor-free outcomes with memory against multiple aggressive tumor models SUMMARY We report on the utility of a "super-adjuvant" nanoparticle (NP) system as a modular, customizable platform for next-generation cancer vaccination. Using nanomaterials engineering technology, we aim to harness not only the effective adjuvanticity of whole-pathogen vaccines, but also the safety of subunit vaccines. Our lipid-based NP platform co-encapsulates agonists of the stimulator of interferon genes (STING) and Toll-like receptor 4 (TLR4) pathways to promote synergistic production of type I interferons and other proinflammatory cytokines in innate antigen-presenting dendritic cells and macrophages. Compared to empty NPs and free agonists, dual-adjuvant NPs administered with antigenic peptides or tumor cell lysate promote increased antigen processing and presentation, drain efficiently to nearby lymph nodes, increase polyfunctional tumor-specific T and B cells, and improve tumor-free outcomes upon vaccination and subsequent challenge with multiple aggressive tumor cells. Graphical Abstract The vaccine combines two immune-stimulating molecules (adjuvants) in a tiny lipid nanoparticle that enhances both innate and adaptive immune responses. The innate immune system acts as the body’s first line of defense, responding quickly and non-specifically to invaders using cells that release inflammatory signals. The adaptive immune system takes longer to activate but provides a targeted, long-lasting response, training T-cells and B- cells to recognize and remember specific threats. Together, they form a coordinated defense: the innate system alerts and activates the adaptive system, which then delivers precise and durable immunity.
December 9, 2025 at 5:02 PM